Reprogramming central carbon metabolism for the efficient de novo biosynthesis of D-chiro-inositol in Escherichia coli

Keywords

Escherichia coli / Metabolic engineering / D-chiro-inositol / Central metabolic regulation / Fed-batch fermentation

References

[1] Bevilacqua A, Dragotto J, Giuliani A, Bizzarri M. Myo-inositol and d-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J Cell Physiol. 2019, 234(6): 9387-9398.

[2] Cetnar DP, Salis HM. Systematic quantification of sequence and structural determinants controlling mRNA stability in bacterial operons. ACS Synth Biol. 2021, 10(2): 318-332.

[3] Chiofalo B, Laganà AS, Palmara V, Granese R, Corrado G, Mancini E, Vitale SG, Ban Frangež H, Vrtačnik-Bokal E, Triolo O. Fasting as possible complementary approach for polycystic ovary syndrome: Hope or hype?. Med Hypotheses. 2017, 105: 1-3.

[4] Dai J, Jiang K, Du Y, Ji SM, Shen XL, Wang J, Sun XX, Yuan QP. Establishing genetically stable Escherichia coli for effective myo-inositol production. Bioresour Technol. 2025, 443: 133874.

[5] Dinicola S, Chiu TTY, Unfer V, Carlomagno G, Bizzarri M. The rationale of the myo-inositol and d-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol. 2014, 54(10): 1079-1092.

[6] Farasat I, Kushwaha M, Collens J, Easterbrook M, Guido M, Salis HM. Efficient search, mapping, and optimization of multi-protein genetic systems in diverse bacteria. Mol Syst Biol. 2014, 106731.

[7] Gambioli R, Forte G, Aragona C, Bevilacqua A, Bizzarri M, Unfer V. The use of d-chiro-inositol in clinical practice. Eur Rev Med Pharmacol Sci. 2021, 251438-446.

[8] Gambioli R, Montanino Oliva M, Nordio M, Chiefari A, Puliani G, Unfer V. New insights into the activities of d-chiro-inositol: a narrative review. Biomedicines. 2021.

[9] Gu Y, Deng JY, Liu YF, Li JH, Shin H-D, Du GC, Chen J, Liu L. Rewiring the glucose transportation and central metabolic pathways for overproduction of N-Acetylglucosamine in Bacillus subtilis. Biotechnol J. 2017.

[10] Ji GH, Jin X, Shi F. Metabolic engineering Corynebacterium glutamicum for D-chiro-inositol production. World J Microbiol Biotechnol. 2024, 40(5): 154.

[11] Kachhawa G, Senthil Kumar KV, Kulshrestha V, Khadgawat R, Mahey R, Bhatla N. Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: a randomized open-label study. Int J Gynaecol Obstet. 2022, 1582278-284.

[12] Kiani AK, Paolacci S, Calogero AE, Cannarella R, Di Renzo GC, Gerli S, Della Morte C, Busetto GM, Berardinis E, Del Giudice F, Stuppia L, Facchinetti F, Dinicola S, Bertelli M. From myo-inositol to d-chiro-inositol molecular pathways. Eur Rev Med Pharmacol Sci. 2021, 25(5): 2390-2402.

[13] Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010, 16(11-12): 543-552.

[14] Li JZ, He TY, Zhao JJ, Pang Y, Zhang YY, Liu YH, Sun X, Li Y, Lu FP, Li QG. Combination of metabolic engineering and high-throughput screening to realize high-producing Lacto-N-triose II in Escherichia coli. J Agric Food Chem. 2025, 73(28): 17769-17775.

[15] López-Gambero AJ, Sanjuan C, Serrano-Castro PJ, Suárez J, de Rodríguez Fonseca F. The biomedical uses of inositols: a nutraceutical approach to metabolic dysfunction in aging and neurodegenerative diseases. Biomedicines. 2020.

[16] Michon C, Kang C-M, Karpenko S, Tanaka K, Ishikawa S, Yoshida K-I. A bacterial cell factory converting glucose into scyllo-inositol, a therapeutic agent for Alzheimer’s disease. Commun Biol. 2020, 3(1): 93-93.

[17] Ng CY, Farasat I, Maranas CD, Salis HM. Rational design of a synthetic Entner–Doudoroff pathway for improved and controllable NADPH regeneration. Metab Eng. 2015, 29: 86-96.

[18] Pintaudi B, Di Vieste G, Bonomo M. The effectiveness of myo-inositol and d-chiro inositol treatment in type 2 diabetes. Int J Endocrinol. 2016, 2016: 9132052.

[19] Pupel P, Szablińska-Piernik J, Lahuta LB. Two-step d-ononitol epimerization pathway in Medicago truncatula. Plant J. 2019, 100(2): 237-250.

[20] Ramp P, Lehnert A, Matamouros S, Wirtz A, Baumgart M, Bott M. Metabolic engineering of Corynebacterium glutamicum for production of scyllo-inositol, a drug candidate against Alzheimer’s disease. Metab Eng. 2021, 67: 173-185.

[21] Ramp P, Pfleger C, Dittrich J, Mack C, Gohlke H, Bott M. Physiological, biochemical, and structural bioinformatic analysis of the multiple inositol dehydrogenases from Corynebacterium glutamicum. Microbiol Spectr. 2022, 105e0195022.

[22] Ramp P, Mack C, Wirtz A, Bott M. Alternative routes for production of the drug candidate d-chiro-inositol with Corynebacterium glutamicum using endogenous or promiscuous plant enzymes. Metab Eng. 2023, 78: 1-10.

[23] Reis AC, Salis HM. An automated model test system for systematic development and improvement of gene expression models. ACS Synth Biol. 2020, 9113145-3156.

[24] Ricaña CL, Dick RA. Inositol phosphates and retroviral assembly: a cellular perspective. Viruses. 2021.

[25] Siedler S, Bringer S, Blank LM, Bott M. Engineering yield and rate of reductive biotransformation in Escherichia coli by partial cyclization of the pentose phosphate pathway and PTS-independent glucose transport. Appl Microbiol Biotechnol. 2012, 93(4): 1459-1467.

[26] Sun WC, Tang YL, Tian YH, Liu ZK, Xiong WW, Zhang HS, Chen L, Wu HY, Ma Q, Xie XX. Robust production of N-acetyl-glucosamine in engineered Escherichia coli from glycerol-glucose mixture. Synth Syst Biotechnol. 2025, 10(3): 1014-1026.

[27] Tang E, Shen XL, Wang J, Sun XX, Yuan QP. Synergetic utilization of glucose and glycerol for efficient myo-inositol biosynthesis. Biotechnol Bioeng. 2020, 117(4): 1247-1252.

[28] Thomas MP, Mills SJ, Potter BVL. The “other” inositols and their phosphates: synthesis, biology, and medicine (with recent advances in myo-inositol chemistry). Angew Chem Int Ed Engl. 2016, 55(5): 1614-1650.

[29] Vitale SG, Corrado F, Caruso S, Di Benedetto A, Giunta L, Cianci A, D’Anna R. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes—a randomized and open-label, placebo-controlled clinical trial. Int J Food Sci Nutr. 2021, 72(5): 670-679.

[30] Xu C, Wang ZL, Sun L, Gu ZH, Guo ZP, Ledesma-Amaro R, Zhang L. Sustainable bioprocess for D-chiro-inositol production via metabolic engineering of Saccharomyces cerevisiae. Chem Eng J. 2026, 527: 171466.

[31] Yoshida K-I, Bott M. Microbial synthesis of health-promoting inositols. Curr Opin Biotechnol. 2024, 87103114.

[32] Yoshida K-I, Yamaguchi M, Morinaga T, Ikeuchi M, Kinehara M, Ashida H. Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. Appl Environ Microbiol. 2006, 72(2): 1310-1315.

[33] Yoshida K-I, Yamaguchi M, Morinaga T, Kinehara M, Ikeuchi M, Ashida H, Fujita Y. Myo-inositol catabolism in Bacillus subtilis. J Biol Chem. 2008, 2831610415-10424.

[34] You R, Wang L, Shi CR, Chen H, Zhang SS, Hu MR, Tao Y. Efficient production of myo-inositol in Escherichia coli through metabolic engineering. Microb Cell Fact. 2020, 19(1): 109.

[35] Zhang QQ, Wang XL, Luo HY, Wang YR, Wang Y, Tu T, Qin X, Su XY, Huang HQ, Yao B, Bai YG, Zhang J. Metabolic engineering of Pichia pastoris for myo-inositol production by dynamic regulation of central metabolism. Microb Cell Fact. 2022, 211112.

[36] Zhu XW, Wu YK, Lv XQ, Liu YF, Du GC, Li JH, Liu L. Combining CRISPR-Cpf1 and recombineering facilitates fast and efficient genome editing in Escherichia coli. ACS Synth Biol. 2022, 1151897-1907.

Funding

National Key Research and Development Program for Food Nutrition and Safety(2023YFF1104100)

National Natural Science Foundation of China(32300064)

Scientific Research Innovation Capability Support Project for Young Faculty(ZYGXQNJSKYCXNLZCXM-A6)

the Fundamental Research Funds for the Central Universities(JUSRP622028)

Research Program of State Key Laboratory of Food Science and Resources, Jiangnan University(SKLF-ZZB-202405)

Jiangsu Basic Research Center for Synthetic Biology(20233003)

RIGHTS & PERMISSIONS

Jiangnan University